Screener
Axsome Therapeutics AXSM Finance Lease Liabilities
Finance Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityNoncurrent.
The source filing: Axsome Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 5:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204274
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Contingent consideration, non-current | 73,730 | 77,540 |
| Loan payable, long-term | 117,850 | 117,746 |
| Operating lease liability, long-term | 22,385 | 23,182 |
| Finance lease liability, long-term | 5,844 | 4,206 |
| Total liabilities | 659,020 | 601,510 |
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value per share (10,000,000 shares authorized, none issued and outstanding) | — | — |
| Common stock, $0.0001 par value per share (150,000,000 shares authorized, 51,420,445 and 50,882,766 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively) | 5 | 5 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Axsome Therapeutics's finance lease liabilities?
- Axsome Therapeutics (AXSM) reported finance lease liabilities of $5.84M in Q1 2026.
- How has Axsome Therapeutics's finance lease liabilities changed year-over-year?
- Axsome Therapeutics's finance lease liabilities increased by 58.8% year-over-year, from $3.68M to $5.84M.
- What does finance lease liabilities mean?
- Present value of future payments on leases classified as finance leases under ASC 842 — treated similarly to debt on the balance sheet.
Ask your AI about Axsome Therapeutics's finance lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude